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Abstract
Background: Anandamide (AEA) is an endogenous lipid mediator that exerts several effects in the brain as well as in
peripheral tissues. These effects are mediated mainly by two types of cannabinoid receptors, named CB1R and CB2R, making
AEA a prominent member of the ‘‘endocannabinoid’’ family. Also immune cells express CB1 and CB2 receptors, and possess
the whole machinery responsible for endocannabinoid metabolism. Not surprisingly, evidence has been accumulated
showing manifold roles of endocannabinoids in the modulation of the immune system. However, details of such a
modulation have not yet been disclosed in primary human T-cells.
Methodology/Significance: In this investigation we used flow cytometry and ELISA tests, in order to show that AEA
suppresses proliferation and release of cytokines like IL-2, TNF-a and INF-c from activated human peripheral T-lymphocytes.
However, AEA did not exert any cytotoxic effect on T-cells. The immunosuppression induced by AEA was mainly dependent
on CB2R, since it could be mimicked by the CB2R selective agonist JWH-015, and could be blocked by the specific CB2R
antagonist SR144528. Instead the selective CB1R agonist ACEA, or the selective CB1R antagonist SR141716, were ineffective.
Furthermore, we demonstrated an unprecedented immunosuppressive effect of AEA on IL-17 production, a typical cytokine
that is released from the unique CD4+ T-cell subset T-helper 17.
Conclusions/Significance: Overall, our study investigates for the first time the effects of the endocannabinoid AEA on
primary human T-lymphocytes, demonstrating that it is a powerful modulator of immune cell functions. In particular, not
only we clarify that CB2R mediates the immunosuppressive activity of AEA, but we are the first to describe such an
immunosuppressive effect on the newly identified Th-17 cells. These findings might be of crucial importance for the rational
design of new endocannabinoid-based immunotherapeutic approaches.
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Introduction
Anandamide (N-arachidonoylethanolamine, AEA) is an endog-
enous arachidonic acid derivative which functionally belongs to
the family of endocannabinoids (ECs), an evergrowing class of lipid
mediators isolated from brain and peripheral tissues [1,2]. AEA
exerts its action through binding and activation of cannabinoid
receptors, CB1R and CB2R [3]. These receptors are differentially
distributed among cells, with CB1R being preferentially expressed
in the brain and in other neural tissues, whilst CB2R is found
mainly in cells of the immune system [4,5]. The presence of
endogenous ligands for the cannabinoid receptors has increased
awareness of the potential importance of endocannabinoids in
regulating and fine-tuning several processes, including neuropro-
tection [6] and immune responses [7]. When stimulated, immune
cells up-regulate particular receptors or express new ones. This
scenario has been demonstrated also for CBRs, since several
stimuli have been reported to differently modulate both cannabi-
noid receptor subtypes in immune cells, like mouse splenocytes,
Jurkat T-cells, mouse macrophages and microglia, as well as
human tonsillar B cells and dendritic cells [8]. In addition, it
has been shown that chronic marijuana smoking increases CB1R
and CB2R mRNA in peripheral blood mononuclear cells [8].
Modulation of CBRs gives support to a regulatory role of
endocannabinoids in immune responses, however the molecular
details of this activity have yet to be fully elucidated. So far, AEA
has been detected in different immune cells, including dendritic
cells, macrophages, microglia, and lymphocytes [9]. Moreover,
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and robust increase in AEA levels, further supporting a role
for AEA in immune regulation [10]. For instance, AEA sup-
presses LPS-induced nitric oxide production by mouse peritoneal
macrophages [11], and LPS-induced cytokine mRNA expression
in rat microglial cells [12]. In addition, AEA decreases mitogen-
induced T and B cell proliferation [13], suppresses CD8 T
lymphocyte migration [14], and induces apoptosis in macrophages
[15] and dendritic cells [16]. In the present study we sought to
better define the role of AEA in modulating immune functions of
primary human T cells, with a special focus on the key regulators
of autoimmune inflammation: Th17 lymphocytes [17].
Materials and Methods
Cell preparation
Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated by Ficoll-hystopaque gradient centrifugation
(Pharmacia, Uppsala, Sweden) and cultured at 10
6 cells/ml in
RPMI 1640 medium supplemented with 10% (vol/vol) heat-
inactivated human serum (Life Technologies, Grand Island, NY),
2 mM L-glutamine, 20 mM HEPES [N-2-hydroxyethylpipera-
zine-N’2-ethanesulfonic acid] and 10 U/ml penicillin and strep-
tomycin (Life Technologies). Using the Pan T cell Isolation Kit
(Miltenyi Biotec, Germany), highly purified human CD3
+-T cells
were isolated by depletion of CD3
2 non-T cells (negative
selection). The purity of the enriched CD3
+-T cells was evaluated
by Flow Cytometry and was consistently above 90%.
Immunoblotting of Cannabinoid Receptors
Purified human T lymphocytes were lysed with RIPA Buffer
(1% Nonidet P40, 0.1% sodium dodecyl sulphate (SDS), 0.5%
sodium deoxycholate, 0.1% protease inhibitor cocktail, 50 mM
sodium fluoride and 100 mM sodium orthovanadate in phosphate-
buffered saline, PBS), and centrifuged for 30 min at 18000 x g at
4uC. The supernatants were recovered and the protein concen-
tration measured using the Bradford assay. The expression of
CB1R and CB2R was assessed by Western blotting. Cell
homogenates were subjected to 10% SDS-PAGE (50 mg/lane)
under reducing conditions, then gels were electroblotted onto
0.45-mm nitrocellulose filters (Bio-Rad, Hercules, CA) and were
immunoreacted with anti-CB1R (1:250) or anti-CB2R (1:500)
polyclonal antibodies (Cayman Chemical Co., Ann Arbor, MI), or
with anti-b-actin monoclonal antibody (1:5000, Bio-Rad). GAR-
AP (1:2000, Santa Cruz Biotechnologies, Santa Cruz, CA) or
GAM-AP (1:10000, Bio-Rad) were used as second antibody. The
specificity of anti-CB1 or anti-CB2 antibodies was ascertained by
preincubating 1 mg of each antibody with 10 mg of the specific
blocking peptide (Cayman Chemical Co., Ann Arbor, MI).
qRT-PCR Analysis
RNA was extracted from purified human T-lymphocytes using
the RNeasy extraction kit (Qiagen, Crawley, UK), as suggested by
the manufacturer. Quantitative real time reverse transcriptase
(qRT)-PCR assays were performed using the Super-Script III
Platinum two-step qRTPCR kit (Invitrogen). One mg of total RNA
was used to produce cDNA with 10 units/ml SuperScript III
reverse transcriptase, in the presence of 2 units/ml RNaseOUT,
1.25 mM oligo(dT)20, 1.25 ng/ml randomhexamers, 5 mM
MgCl2, 0.5 mM dNTP mix, and diethyl pyrocarbonate-treated
water. The reaction was performed using the following qRT-PCR
program: 25uC for 10 min, 42uC for 50 min, 85uC for 5 min, then
after addition of 0.1 unit/mlo fEscherichia coli RNase H, the
product was incubated at 37uC for 20 min. The target transcripts
were amplified by means of an ABI PRISM 7700 sequence
detector system (Applied Biosystems, Foster City, CA) using the
following primers: human CB1R F1 (59-CCTTTTGCT-
GCCTAAATCCAC-39) and human CB1R R1 (59-CCACTGCT-
CAAACATCTGAC-39); human CB2R F1 (59-TCAACCCTGT-
CATCTATGCTC-39) and human CB2R R1 (59-AGTCAGTCC-
CAACACTCATC-39). b-Actin was used as housekeeping gene for
quantity normalization. One ml of the first strand of cDNA
product was used for amplification (in triplicate) in a 25 ml reaction
solution, containing 12.5 ml of PlatinumSYBRGreenqPCRSuper-
Mix UDG (Invitrogen) and 10 pmol of each primer. The following
PCR program was used: 95uC for 10 min, 40 amplification cycles
at 95uC for 30 s, 56uC for 30 s, and 72uC for 30 s.
Confocal Microscopy
Purified T-lymphocytes were seeded on Chamberslides (Lab-
Tek) at 1610
5 cells/well and were stimulated or not with anti-
CD3 and anti-CD28 polyclonal antibodies for 24 h. Cells were
then fixed and were stained with anti-CB1R or anti-CB2R specific
antibodies. The surface localization of cannabinoid receptors was
visualized by confocal microscopy (Leica TCS SP), performing
image acquisition through the LAS AF program (Leica).
[
35S]GTPcS Assay
Resting or anti-CD3/anti-CD28-activated purified human T-
lymphocytes (2.5610
6 cells/test) were incubated in the presence or
absence of the synthetic agonist of cannabinoid receptors
CP55.940 (2.5 mM), for 60 min at room temperature in 20 mM
HEPES, 100 mM NaCl, 5 mM MgCl2, 0.2% (w/v) BSA buffer
(pH 7.6), supplemented with 20 mg/ml saponin (Sigma Chemical
Co., St. Louis, MO), 25 mM GDP (Sigma) and 0.3 nM
[
35S]GTPcS (Perkin Elmer Life Sciences). Nonspecific binding
was determined in the absence of agonist and in the presence of
10 mM unlabeled GTPcS (Perkin Elmer Life Sciences), as reported
[18].
Flow Cytometry Analysis
Freshly isolated PBMCs were left untreated or were pre-treated
with 2.5 mM AEA (Sigma); cells were stimulated with plate-bound
anti-CD3 (clone T3D; 5 mg/ml) and soluble anti-CD28 antibody
(2 mg/ml) (e-Bioscience) for 48 hours. Cells were then washed
twice and stained with anti-CD3, anti-CD8, anti-CB1R and anti-
CB2R antibodies in PBS, supplemented with 0.5% FCS and
0.02% NaN3. Surface receptors expression was analysed by FACS
(FACSCanto, Becton-Dickinson).
Antibodies
Cells were stained for Cytometry analysis using the antibodies
detailed in Table 1.
Proliferation Assay
T-cells were plated at 1610
5 cells/well and were treated or not
with 2.5 mM AEA and selective CB1Ro rC B 2R agonists, ACEA
(arachidonoyl-2-chloroethylamide) and JWH-015 ((2-methyl-
1-propyl-1H-indol-3-yl)-1-napthalenylmethanone) respectively, or
antagonists (SR141716 (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-
(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydro-
chloride) [SR1], and SR144528 (N-(1,S)-endo-1,3,3-trimethyl-
bicycle(2,2,1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4 methyl-
benzyl)-pyrazole-carboxamide) [SR2], respectively). CBRs antago-
nists were used in combination with their respective agonist,
according to the experimental conditions. After treatments, cells
were plate-bound and then were stimulated with purified anti-CD3
Anandamide Inhibits T-Cells
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e-Bioscience). Proliferation of AEA-pretreated PBMCs was assessed
by monitoring carboxyfluorescein diacetate (CFDA; Molecular
Probes) dilution, after stimulation with CD3/CD28. Cell divisions
were followed by flow cytometry every two days for one week. All
flow cytometric data were analyzed with Flowjo software (Treestar,
Ashland, OR). Proliferation was also assessed by [
3H]thymidine
incorporation, labelling unstimulated or stimulated cells with
1 mCi/well [
3H]thymidine (Perkin Elmer) after 4 days of culture.
After further 12 hours, cell proliferation was determined using a
beta-plate reader (Tomtec, Gaithersburg, MD), according to the
manufacturer’s instructions.
ELISA
T cells were plated at 1610
5cells/well and were left untreated
or were pre-treated with 2.5 mM AEA, or with JWH-015, ACEA,
SR1 or SR2, each used at 1.0 mM. Each antagonist was used
in combination with its respective agonist, according to the
experimental conditions. After treatments, cells were plate-bound
and then were stimulated with purified anti-CD3 (clone T3D;
5 mg/ml) and soluble anti-CD28 antibody (2 mg/ml; e-Bioscience).
Cells were maintained at 37uC for 24 hours and then supernatants
were collected. Cytokines were determined by a standard 2-site
sandwich enzyme-linked immunosorbent assay (ELISA), using
enhanced protein-binding ELISA plates (Nunc Maxisorp; Nunc
Maxi, Roskilde, Denmark). Antibody for IL-2 was purchased from
Roche, while antibodies for TNF-a and IFN-c were purchased
from Pierce Endogen.
Intracellular Staining
Freshly isolated PBMCs were pre-treated with 2.5 mM AEA
and/or with selective CB1Ro rC B 2R agonists or antagonists, and
then stimulated with 1 mM phorbol 12-myristate 13-acetate (PMA,
Sigma) and 10 mM ionomycin (Sigma) for 6 hours, in order to
allow cytokines synthesis. Each antagonist was used in combina-
tion with its respective agonist, according to the experimental
Table 1. Details of the antibodies used in the study.
ANTIBODY MANUFACTURER DILUTION
CB1R Affinity Bioreagents 1:200
CB2R Cayman Chemicals 1:200
CD3
(APC-Alexa Fluor750)
eBioscience 1:40
CD8 (Pe-Cy7) Beckman Coulter Inc. 1:40
Goat-anti-rb IgG
(Alexa Fluor 633)
Invitrogen, Molecular Probes 1:200
TNF-a-APC eBiosciences 1:40
IFN-c-PE BD Biosciences Pharmigen 1:40
IL-17-PE eBiosciences 1:20
doi:10.1371/journal.pone.0008688.t001
Figure 1. Analysis of CB1R and CB2R expression in resting and activated primary human T-lymphocytes. Freshly isolated T-lymphocytes
were either left untreated or treated with 5 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for the indicated periods of time (24–72 hours). Panels A–D: Cells
were lysed and the homogenates were assayed for CB1R and CB2R protein by Western blot analysis. CB1R and CB2R protein levels were quantified by
densitometric analysis, and were normalized to beta-actin. The results were expressed as total amount of receptors over 24 hours and 72 hours of
stimulation (A, B and C) (average value of all samples) as well as CB2Rt oC B 1R ratio (Panel D). Panel E: Cells were washed in PBS, and then mRNA was
isolated and analysed by qRT-PCR using specific primers for CB1R and CB2R. Data are representative of 4 independent experiments.
doi:10.1371/journal.pone.0008688.g001
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brefeldine A (Sigma) 4 hours before the end of stimulation. At the
end of the incubation, cells were washed twice and were stained
with anti-CD3 and anti-CD8 antibodies in PBS, supplemented
with 0.5% FCS and 0.02% NaN3. Cells were fixed with 4%
paraformaldehyde (Sigma) for 10 min at room temperature. Cells
were stained intracellulary with anti-TNFa-APC, anti-IFNc-PE,
or anti-IL17-PE and analysed on the flow cytometer.
Statistics
Statistical analysis was performed by Prism 4 (GraphPAD
Software for Science, San Diego, CA), using paired Student’s t-test
and assuming an unequal variance with 95% confidence levels.
Only p values ,0.05 were considered significant.
Results
Effect of AEA on CB1R and CB2R expression
Initial studies were performed to assess the modulation, if any,
of cannabinoid receptors expression by purified T lymphocytes
following their activation. Fig. 1A shows that activated T-cells
express higher levels of CB2R than CB1R at two distinct
experimental time points (24 h and 72 h). These immunoreactive
bands were fully erased by preincubation of anti-CB1 and anti-
CB2 antibodies with their specific blocking peptides, demonstrat-
ing antibody specificity (Fig. 1A). The pattern of CBRs expression
in resting and activated T-lymphocytes can be better appreciated
by means of densitometric analysis of the blots, shown in
Figs. 1B–D. In fact, CB2R expression in activated cells displayed
a ,2.5-fold increase compared to that of CB1R. However, no
significant difference could be observed between controls and anti-
CD3/anti-CD28-treated cells at both experimental times. In order
to further analyze CBRs expression, we quantified the mRNA
levels of the receptors in resting and anti-CD3/anti-CD28-
stimulated T-cells; we found that CB2R mRNA was ,6-fold
higher than that of CB1R under both conditions (Fig. 1E). These
results led to the hypothesis of a possible re-localization of
cannabinoid receptors within the cell upon activation. In order to
substantiate this concept, the expression of CB1R and CB2R was
evaluated on cell surface by means of cytometric analysis and
confocal microscopy. As shown in Fig. 2A, upon polyclonal
stimulation with anti-CD3 and anti-CD28, T-lymphocytes showed
a significant increase in CB1R and CB2R, with the levels of the
latter being significantly higher than those of CB1R. These effects
could be observed in both CD4
+CD3
+ and CD8
+CD3
+ lympho-
cytes, and were also confirmed by confocal imaging (Fig. 2B),
showing that fluorescence intensity of CB2R was higher than that
of CB1R in activated T-cells. In addition, we found that treatment
with the CBRs synthetic agonist CP55.940 significantly increased
[
35S]GTPcS binding in activated, but not in resting, T-cells
(Fig. 2C).
Effect of AEA on T-cell proliferation and IL-2 production
Since activated lymphocytes relocalize CB2 and (to a lesser
extent) CB1 receptors, we set out to investigate the effect of CB
receptor stimulation on lymphocyte function. In a preliminary set
of experiments we tested by cytofluorimetric analysis the effect of
different doses of AEA (up to 5.0 mM with 0.5 mM increments) on
human T-cell proliferation. We found that AEA dose-dependently
reduced cell proliferation, down to a minimum of ,40% of
controls at 2.5 mM, without any further reduction at higher doses
(not shown). Therefore, 2.5 mM AEA was chosen to perform all
subsequent experiments. First, we measured cell proliferation
following polyclonal stimulation, alone or in the presence of the
CBR agonist AEA. Fig. 3 shows that 2.5 mM AEA strongly
suppresses anti-CD3/anti-CD28-induced CD4+ and CD8+ T-
lymphocyte proliferation. This effect was not due to an induction
of necrosis or apoptosis, as assessed by testing cell viability and/or
DNA fragmentation through 7-AAD labeling. In addition, the
anti-proliferative action of AEA was counteracted by the selective
CB2R antagonist SR2, used at 1.0 mM, thus suggesting a major
involvement of type-2 cannabinoid receptor in this activity of
AEA. Such an involvement of CB2R was further validated by
using the selective CB2R agonist JWH-015 (at 1.0 mM), that
produced a strong and significant inhibition of T-lymphocytes
proliferation. Instead, the CB1R selective agonist ACEA was
ineffective, when used at 1.0 mM. The anti-proliferative effect of
AEA was also confirmed by [
3H]-thymidine incorporation assays
(Fig. 4A), in which we demonstrated that AEA significantly
inhibited DNA synthesis, and that JWH-015 mimicked this action
whereas ACEA did not. Moreover, SR1 or SR2 were able to
significantly reduce inhibition of [
3H]-thymidine incorporation
induced by AEA. Incidentally, it should be recalled that AEA is
also an endogenous agonist of type-1 vanilloid receptors (TRPV1)
[19]. We found that human T lymphocytes express mRNA levels
of TRPV1 similar to those of CB1R, but they failed to express
Figure 2. Surface expression of CB1R and CB2R on primary
human T-lymphocytes. Freshly isolated human T-lymphocytes were
stimulated or not with anti-CD3 and anti-CD28 for 24 hours. Panels A–
B: Surface expression of CB1R and CB2R was reported as MIF (medium
intensity of fluorescence) values on a FACS-Canto, gating for CD4
+CD3
+
and CD4
2CD3
+ cells (A), and by confocal microscopy staining with anti-
CD3, and anti-CB1R or anti-CB2R( B). Panel C: Resting or activated T-
cells were either left untreated or incubated with 2.5 mM CP55.940 (CP),
20 mg/ml saponin, 25 mM GDP and 0.3 nM [
35S]GTPcS. The amount of
[
35S]GTPcS bound is reported as counts per min (cpm) per 2.5610
6 cells.
* Indicates p,0.005 versus CD3/CD28-treated cells. Data are represen-
tative of 4 independent experiments.
doi:10.1371/journal.pone.0008688.g002
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8688Figure 3. Effect of AEA on cell proliferation versus cell viability in anti-CD3/anti-CD28-stimulated T-lymphocytes. Purified resting or
CD3/CD28-activated T-lymphocytes (1610
5 cells/well) were either left untreated or treated with 2.5 mM AEA and/or cannabinoid receptors agonists
or antagonists (each at 1.0 mM). Cells were labelled by means of CFDA-staining as well as by 7-AAD dye, and proliferating cells were analyzed with
Flow Cytometry as described in Materials and Methods.
doi:10.1371/journal.pone.0008688.g003
Anandamide Inhibits T-Cells
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8688TRPV1 protein. Consistently, we found that the TRPV1 agonist
capsaicin (at doses up to 10 mM) did not affect T-cell proliferation
assessed by FACS analysis, and that the TRPV1 antagonist
capsazepine (1 mM) did not affect the antiproliferative activity of
2.5 mM AEA (data not shown). Both capsaicin and capsazepine
were used at doses previously shown to be effective on the target
receptor in immune cells [20]. Furthermore, Fig. 4B shows that
AEA effectively suppressed the release from T-lymphocytes of the
crucial T cell growth factor IL-2 compared to anti-CD3/anti-
CD28-treated controls (134661 pg/ml versus 15306161 pg/ml;
n=9). Again, both SR1 and SR2 minimized this effect of AEA,
whereas ACEA was ineffective and JWH-015 strongly reduced IL-
2 release (145624 pg/ml; n=4). The latter effect was minimized
by SR2 (13116346 pg/ml; n=4).
Effect of AEA on cytokine release
Next, we ascertained the possible impact of AEA on the
production and release of several cytokines from T-cells. A
summary of the amount of cells producing the cytokines analyzed
under all experimental conditions tested is reported in Tables 2
and 3. We found that AEA suppresses TNF-a and IFN-c
production from PMA/ionomycin-activated T-lymphocytes, both
in CD4
+ and CD8
+ subpopulations (Fig. 5). Suppression of TNF-
a and IFN-c production by AEA was significantly counteracted by
both CB1R and CB2R antagonists, but SR2 showed a larger effect
Figure 4. Effect of AEA on IL-2 dependent anti-CD3/anti-CD28-
stimulated T-cell proliferation. Purified resting or CD3/CD28-
activated T-lymphocytes (1610
5 cells/well) were either left untreated
or treated with 2.5 mM AEA and/or cannabinoid receptors agonists or
antagonists (each at 1.0 mM). Panel A: Treated or untreated cells were
incubated overnight with [
3H]-thymidine. Levels of [
3H]-thymidine
incorporation were measured as reported in Materials and Methods.
Data were reported as the mean 6 SD of 8 independent experiments. *
Indicates p,0.001 versus CTRL cells, # p,0.01 versus CD3/CD28-treated
cells,
1 p,0.001 versus CD3/CD28+AEA-treated cells, and
D p,0.01
versus CD3/CD28+JWH-015-treated cells. Panel B: Supernatants of
treated or untreated cells cultured for 24 hours were collected, and IL-2
levels were quantified by means of ELISA. Data are reported as the
mean (6 SD) of 6 independent experiments. * Indicates p,0.001 versus
CTRL cells, # p,0.01 versus CD3/CD28-treated cells,
1 p,0.05 versus
CD3/CD28+AEA-treated cells,
11 p,0.001 versus CD3/CD28+AEA-treated
cells, and
D p,0.01 versus CD3/CD28+JWH-015-treated cells.
doi:10.1371/journal.pone.0008688.g004
Table 2. Amount of T-lymphocyte subpopulations producing
IFN-c or TNF-a.
CD4
+ CD8
+
IFNc TNFa IFNc TNFa
CTRL 0.0360.06 0.0360.04 0.0660.10 0.0260.03
PMA/IONO
a 16.8064.30* 29.9067.30* 29.6068.40* 25.0069.30*
PMA/IONO + AEA
b 0.0360.60
# 0.4961.30
# 1.0062.70
# 0.9661.80
#
PMA/IONO + AEA
+ SR1
c
13.3063.90
1 22.80610.40
1 21.7066.90
1 20.4669.00
1
PMA/IONO + AEA
+ SR2
d
16.3065.10
1 27.90611.60
1 26.6068.60
1 24.3469.78
1
PMA/IONO + AEA
+ SR1/SR2
15.6063.03
1 27.3663.70
1 26.9065.90
1 24.7369.90
1
PMA/IONO + ACEA
e 11.1560.97 24.6066.20 21.6366.16 21.91611.00
PMA/IONO + ACEA
+ SR1
12.0061.41 25.9263.20 21.8067.30 22.6269.80
PMA/IONO + JWH
f 0.0260.30
# 2.1262.10
# 0.6060.08
# 6.4063.20
#
PMA/IONO + JWH
+ SR2
16.2062.80
D 26.6862.98
D 30.0067.20
D 23.3069.20
D
aPMA/IONO =1 mM/10 mM.
bAEA =2.5 mM.
cSR1 =1 mM.
dSR2 =1 mM.
eACEA =1 mM.
fJWH =1 mM.
*Denotes p,0.001 versus CTRL; # denotes p,0.001 versus PMA/IONO;
1 denotes p,0.001 versus PMA/IONO + AEA;
D denotes p,0.001 versus
PMA/IONO + JWH.
doi:10.1371/journal.pone.0008688.t002
Table 3. Amount of CD4+ T-lymphocyte subpopulation
producing IL-17.
CD4+IL-17+
CTRL 0.0660.06
PMA/IONO
a 0.9460.18
*
PMA/IONO + AEA
b 0.0260.01
#
PMA/IONO + AEA + SR1
c 0.8360.18
1
PMA/IONO + AEA + SR2
d 0.9760.22
1
PMA/IONO+AEA+SR1/SR2 1.0260.22
W
PMA/IONO + ACEA
e 0.7660.16
PMA/IONO + ACEA + SR1 0.7760.14
PMA/IONO + JWH
f 0.0160.01
#
PMA/IONO + JWH +SR2 0.9460.19
D
aPMA/IONO =1 mM/10 mM.
bAEA =2.5 mM.
cSR1 =1 mM.
dSR2 =1 mM.
eACEA =1 mM.
fJWH =1 mM.
*Denotes p,0.01 versus CTRL; # denotes p,0.05 versus PMA/IONO; 1 denotes
p,0.05 versus PMA/IONO + AEA; W denotes p,0.001 versus PMA/IONO + AEA;
D denotes p,0.001 versus PMA/IONO + JWH.
doi:10.1371/journal.pone.0008688.t003
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tion, whereas JWH-015 mimicked the suppressive action of AEA,
and SR2 significantly antagonized this effect. Furthermore, the
production of IL-17 was also analyzed. In fact, this cytokine is
produced only by specialized T-helper cells (Th17), that have been
recently recognized as pivotal players in autoimmune diseases and
in almost every pro-inflammatory process. As shown in Fig. 6,
AEA suppressed IL-17 production from PMA/ionomycin-activat-
ed CD4+ T-lymphocytes, an effect antagonized by both SR1 and
SR2, and was mimicked by JWH-015 but not ACEA. Addition-
ally, Fig. 6 shows the production of IFN-c together with that
of IL-17, in order to demonstrate that the latter cytokine is
produced only by a specific subset of T-cells that, in turn, were
unable to produce IFN-c. Finally, in order to further analyze the
effect of AEA on the cytokine profile, a quantitative analysis
of TNF-a and IFN-c content was performed by means of
ELISA. Figs. 7A–B show that anti-CD3/anti-CD28-activated
T-lymphocytes produced significant amounts of TNF-a and
IFN-c (28546440 pg/ml and 31406230 pg/ml, respectively;
n=6), whereas in T-cells treated with 2.5 mMA E At h er e l e a s eo f
cytokines was remarkably inhibited (TNF-a =101691 pg/ml and
IFN-c =8 0 670 pg/ml; n=6). Interestingly, 1.0 mMS R 1d i dn o t
significantly antagonize the effect of AEA on cytokine release,
whereas 1.0 mMS R 2d i d( T N F - a = 25456311 pg/ml and
IFN-c =2 7 6 1 6489 pg/ml; n=6). In addition, 1.0 mM JWH-015
(TNF-a = 82.33641.74 pg/ml and IFN-c =1256115 pg/ml;
n=4), but not 1.0 mM ACEA, mimicked the activity of AEA,
and 1.0 mM SR2 counteracted this effect of JWH-015 (TNF-a =
26736339 pg/ml and IFN-c =27546506.5 pg/ml; n=4).
Discussion
Since its identification from porcine brain, AEA has been shown
to exert cannabimimetic activities such as the induction of
hypothermia, analgesia, and motor effects. Although first de-
scribed in the nervous system, it is becoming increasingly clear that
AEA plays an important role in modulating the immune system.
The present study clearly shows that AEA is immunosuppressive
when added to activated T-lymphocytes, and that it acts mainly
through CB2R. In the attempt to shed some light on such
immunomodulatory activity of AEA, we first collected evidence for
the alteration of the expression of CB1R and CB2R, as a result of
cell activation. In fact, it is well-documented that immune cells,
when activated, can modulate specific receptors in order to trigger
Figure 5. Effect of AEA on TNF-a versus IFN-c production in activated T-lymphocytes. T-lymphocytes (1610
5 cells/well) were either left
untreated or treated with 2.5 mM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 mM). Cells were then stimulated with PMA/
ionomycin for 6 hours and stained intracellularly with anti-TNFa-APC and anti-IFNc-PE. Levels of intracellular cytokine production were analyzed by
flow cytometry, as detailed in Matherials and Methods, and represent 8 independent experiments.
doi:10.1371/journal.pone.0008688.g005
Anandamide Inhibits T-Cells
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8688and sustain an efficient immune response. Our data not only
demonstrate by means of several techniques that CB2R is by far
more abundant than CB1R in primary human T-cells, but also
that both receptors are recruited on the cell surface upon
activation. To date there is evidence showing that classical
antigenic stimuli, such as LSP or anti-CD3, can modulate both
CB1R and CB2R expression, however there are discrepancies in
the literature especially because of the different experimental
models used, spanning from Jurkat cells to mouse splenocytes [8].
Thus, our analysis of CB1R and CB2R seems to represent the first
evidence of a redistribution of CBRs with an increased localization
on the cell surface, particularly in the case of CB2R. In addition,
[
35S]GTPcS binding data seem to support a receptor ‘‘sensitiza-
tion’’ in a highly purified population of primary human immune
cells, that is CD3
+-T lymphocytes. This seems of interest, since it
allows a better understanding of the role of CB1 versus CB2
receptors in endocannabinoid-mediated immunomodulation of
lymphocytes. Increasing evidence supports indeed that both
receptors are involved in central nervous system autoimmunity,
having particular beneficial effects in the treatment of multiple
sclerosis (MS). Using animal models of MS like experimental
autoimmune encephalomylelitis (EAE), CB1R and CB2R have
been shown to be specific markers of MS plaque cell subtypes [21];
furthermore, CB1R has been proven to mediate suppression of
CNS autoimmune inflammation on neurons, whilst CB2R had the
same anti-inflammatory role on autoreactive T cells [22]. The
present results provide evidence that AEA is able to suppress anti-
CD3/anti-CD28-induced T-cell proliferation mainly via CB2
receptors. In fact, this activity of AEA was minimized by the
CB1R and CB2R antagonists SR1 and SR2, with a major effect
exerted by SR2, and was also mirrored by the CB2R agonist JWH-
015, but not by the CB1R agonist ACEA. At any rate, the anti-
proliferative action of AEA reported herein is in accordance with a
previous report by Schwarz and colleagues [13], where the
suppression of proliferation by mM concentrations of AEA was not
associated to the induction of apoptosis. Indeed, they demonstrat-
ed that AEA is capable of inducing apoptosis only when used at
high doses and even that was at least in part responsible for the
complete inhibition of cell proliferation observed at high
concentrations. The ability of AEA to suppress T-cell proliferation
was also substantiated by its ability to markedly inhibit IL-2 release
from activated T-lymphocytes, again in a CB2R-mediated
manner. This result is consistent with a previous report, where
inhibition of IL-2 release from phytohemagglutinin-stimulated
PBMCs was found to be mediated by CB2R [23]. Incidentally,
here we could demonstrate that TRPV1 was not engaged in this
Figure 6. Effect of AEA on IL-17 versus IFN-c production in activated T-lymphocytes. T-lymphocytes (1610
5 cells/well) were either left
untreated or treated with 2.5 mM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 mM). Cells were then stimulated with PMA/
ionomycin for 6 hours and stained intracellularly with anti-IL17-PE and anti-IFNc-APC. Levels of intracellular cytokine production were analyzed by
flow cytometry, as detailed in Matherials and Methods, and represent 8 independent experiments.
doi:10.1371/journal.pone.0008688.g006
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sive effect of AEA was corroborated by a detailed analysis of the
production of the major cytokines involved in the regulation of T-
lymphocyte responses. Indeed, AEA-induced inhibition of TNF-a
and IFN-c release was predominantly mediated by CB2R, since
cytokine suppression was not significantly reversed by the CB1R
antagonist SR1. However, based on the partial effect of the latter
compound, and on the fact that specific CB1 and CB2 ligands like
ACEA and JWH-015 can only provide indirect evidence of the
involvement of one receptor subtype over the other, a possible
contribution of CB1R to the activity of AEA cannot be ruled out.
In particular, JWH-015 is also a partial agonist of CB1R, although
with lower affinity than for CB2R [24]. In addition, there are
reports that even AEA might not act as a physiological agonist of
CB2R [25], although this endocannabinoid has been shown to
exert manifold CB2R-dependent activities in experimental para-
digms, and more recently its localization within biological
membranes has led to a reconsideration of its role as a true
CB2R agonist in vivo [26,27]. At any rate, it should be stressed that
there are several studies documenting alterations in cytokines
release induced by endocannabinoids on immune cells [28,29], but
none of them has ever been performed on primary human T-
lymphocytes. The capacity of anandamide to suppress the
proinflammatory response of T-cells is of pivotal importance,
because not only it implies a role in inhibiting IFN-c-mediated T-
helper 1 (Th-1) responses, but it could also suggest a potential
down-stream effect of this endocannabinoid also in modulating the
cross-talk between T-lymphocytes and several other immune cells,
including B-cells, macrophages and neutrophils. Activation of
these cells is crucial in several immune-mediated diseases, and in
most recent years a minor subset of T cells has gained centre stage
in the study of the pathogenesis of immune disorders. These cells
produce IL-17, a potent cytokine which contributes to host defense
against extracellular pathogens and which has been clearly shown
to be involved in the development of autoimmune diseases [30].
Current research is investigating the possibility to interfere with
the function of these cells, and the finding that a natural
endogenous compound such as anandamide exerts a suppressive
– but not cytotoxic – effect also on cells with a central role in the
induction of autoimmunity, represents a promising beginning for a
new avenue of research. It should be underlined that most
immunosuppressive therapies involve the use of compounds which
are cytotoxic for T-cells, thus exposing the patients to increased
risk of infections. The finding that AEA preserves cell viability
whilst containing the proinflammatory response represents an
innovative approach in the effort to avoid autoimmune reactivity
without affecting protective immune responses. On this basis, the
present evidence for an immunosuppressive effect of AEA also on
IL-17 production seems very timely, and is suggestive of new
therapeutic approaches that could potentially target autoimmune
diseases.
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